Search Results

South Korea's 2027 Budget Proposal Includes First-Ever Funding for Domestic Nuclear Submarine Development

The South Korean government approved its 2027 budget proposal, with total government spending reaching 820.9 trillion won, approximately 95.6 trillion yen, marking a 12.8% increase from the previous year and setting a record high. The budget proposal has been submitted to the National Assembly for review. President Lee Jae-myung presided over a cabinet meeting at the presidential office on September 1, where the budget proposal was reviewed and approved. Under the plan, the South Korean government intends to increase investment in growth-oriented industries, with approximately 2.5 trillion yen allocated to infrastructure development related to semiconductor manufacturing and artificial intelligence, nearly doubling the scale of the previous year. On the revenue side, the South Korean government expects that as AI demand continues to grow and major semiconductor companies see improved performance, corporate income tax and personal income tax revenues will increase significantly.

2026-09-02

South Korea's Nuclear Safety Regulatory Budget for 2027 Rises to KRW 303 Billion

The Nuclear Safety and Security Commission (NSSC) of South Korea announced on September 1 that it has allocated KRW 303 billion for the 2027 budget, an increase of KRW 10.4 billion from this year. The new budget focuses on areas such as small modular reactor regulation, spent nuclear fuel safety, nuclear facility decommissioning review, environmental radiation monitoring, and nuclear safety information disclosure. Regarding small modular reactors, as non-light water reactor-type small modular reactor development projects aim to obtain licenses by the early 2030s, South Korea will invest KRW 8 billion in R&D to establish a new safety evaluation system. In addition, in line with the preliminary review system set to take effect in November this year, the government has allocated KRW 2.7 billion to conduct preliminary reviews of non-light water reactor-type small modular reactors expected to file applications next year. This system allows applicants to request regulatory review of reactor designs before formally submitting license applications.

2026-09-02

South Korea to Launch National Radiation Monitoring Center in 2027

The South Korean government reviewed and approved the "2027 Budget Plan" at a cabinet meeting on September 1. According to the budget arrangement, South Korea will launch the National Radiation Monitoring Center in 2027 to centrally collect and manage national environmental and marine radioactive information; simultaneously, it will expand the Nuclear Safety Information Sharing Center to strengthen direct communication with residents near nuclear power plants. The Nuclear Safety and Security Commission (NSSC) has allocated 1.4 billion KRW for the construction and operation of the National Radiation Monitoring Center. The project aims to strengthen the environmental radioactivity monitoring and analysis system to address regulatory demands arising from the expansion of domestic nuclear power utilization in South Korea and the increased operation and construction of nuclear facilities in neighboring countries. The National Radiation Monitoring Center is planned...

2026-09-01

Beijing Jiluntai's ¹⁷⁷Lu-JLT003 Injection Receives IND Approval for Treatment of Integrin αvβ3-Positive Malignant Tumors

Beijing Jiluntai Pharmaceutical Co., Ltd. has recently achieved progress in radiopharmaceutical R&D. Its self-developed Class 1 innovative therapeutic radiopharmaceutical ¹⁷⁷Lu-JLT003 Injection (generic name: ¹⁷⁷Lu-AB-3PRGD2) has obtained the Clinical Trial Approval (IND) from the Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA), intended for the treatment of integrin αvβ3-positive malignant tumors. ¹⁷⁷Lu-AB-3PRGD2 is a therapeutic radiopharmaceutical targeting integrin αvβ3. Integrin αvβ3 is highly expressed on various solid tumor cells and tumor neovascular endothelial cells, while showing low expression in normal tissues, a characteristic that...

2026-09-01

Defence Therapeutics Expands Radiopharmaceutical R&D Program to Evaluate Alpha and Beta Emitter Applications

MONTREAL, Quebec, Canada — Biotechnology company Defence Therapeutics Inc. recently announced the expansion of its radiopharmaceutical R&D program to include α and β radioisotopes in its evaluation scope, further validating the application potential of its proprietary Accum® technology in precision oncology. Defence Therapeutics is a publicly traded biotechnology company developing next-generation oncology treatments centered on its Accum® precision drug delivery platform. The company stated that the Accum® technology is designed to facilitate the entry of drug payloads into the intracellular compartment, thereby improving delivery efficiency. This expansion of the radiopharmaceutical program...

2026-09-01

U.S. Molten Salt Solutions Completes $7 Million Seed Funding Round

On August 31, Molten Salt Solutions (MSS), headquartered in New Mexico, U.S., announced that it had completed an oversubscribed $7 million seed funding round. The round was led by Dolby Family Ventures (DFV), with participation from Vanedge Capital Partners, Alumni Ventures, Gaingels, True Ventures, and Future Ventures. MSS primarily develops enriched stable isotopes for the fusion and advanced nuclear energy markets...

2026-09-01

South Korea's Medical Radiation Examinations Exceed 430 Million Annually, with CT Scans Accounting for 67.1% of Radiation Dose

According to the "2025 National Medical Radiation Assessment Yearbook" released by the Korea Disease Control and Prevention Agency on August 28, South Koreans underwent a total of 431.59 million medical radiation examinations last year, averaging 8.4 examinations per person. Over the past five years, the number of medical radiation examinations in South Korea has continued to rise, with last year's figure increasing by 4.6% year-on-year and 29.6% compared to 2021. The report shows that the collective radiation dose from medical radiation examinations in South Korea increased from 136,804.73 person-sieverts in 2021 to 167,659.18 person-sieverts last year, an increase of 22.6%. On a per capita basis, the radiation dose rose from 2.64 millisieverts to 3.24 millisieverts. The Korea Disease Control and Prevention Agency stated that with advances in medical technology, an aging population, and growing demand for health checkups, the use of medical radiation examinations in public healthcare services continues to expand.

2026-08-28

Russia Plans to Complete Development of First Domestic Proton Beam Therapy Cyclotron by 2027

Russian scientists plan to complete the development of the country's first domestically produced proton beam therapy cyclotron by 2027, with commissioning to begin in the same year. This progress was announced by Sergey Gertzog, CEO of the Russian National Institute of Electronics and Atomic Energy (NIIEFA), at the recent Technoprom forum held in Novosibirsk. A proton beam therapy cyclotron is a type of charged particle accelerator that uses magnetic and electric fields to accelerate protons to high-energy states, reaching speeds of one-half to two-thirds the speed of light. The accelerated proton beam can target cancerous tumor areas with relative precision for oncological treatment. According to the schedule outlined in Gertzog's report...

2026-08-28

First Seven Experimental Stations of Russia's SKIF Synchrotron Planned for Commissioning in Summer 2027

The first seven scientific experimental stations at the Siberian Circular Photon Source (SKIF) shared center, located near Novosibirsk, Russia, are planned to begin beam testing in August 2027. According to the center's relevant official, all experimental station equipment has been fully installed, and experts are currently conducting commissioning work. Construction of the SKIF synchrotron was completed in June 2026. Once the project becomes operational, it will utilize synchrotron radiation to help researchers observe the internal structure of matter, obtaining high-precision data on material structure and behavior, which can serve fundamental research and related industrial R&D. As planned, the Budker Institute of Nuclear Physics of the Siberian Branch of the Russian Academy of Sciences will launch beam operation in the main storage ring in September...

2026-08-28

Bristol Myers Squibb to Invest $173 Million in New Radiopharmaceutical Plant in Indiana, USA

Bristol Myers Squibb's RayzeBio will build a new radiopharmaceutical production facility in Whitestown, Indiana, USA, with an investment of $173 million. The project will be located at the Anson Industrial Park in Boone County, with construction planned to begin this year, complementing RayzeBio's existing operational radiopharmaceutical plant in Indianapolis. According to information released by the state of Indiana, the new facility will cover approximately 225,000 square feet. Bristol Myers Squibb expects the two production sites to add 100 new positions by the end of 2029, with annual salaries for new positions expected to exceed $130,000. Bristol Myers Squibb acquired San Diego-based RayzeBio in 2023 for $4.1 billion...

2026-08-28

Russia's SKIF Synchrotron First Scientific User Competition Expected to Launch in Second Half of 2027

The competition to select the first research teams for the Siberian Circular Photon Source (SKIF) synchrotron in Russia is planned for the second half of 2027. Valery Bukhtiyarov, Director of the Boreskov Institute of Catalysis of the Siberian Branch of the Russian Academy of Sciences, stated at the Technoprom-2026 forum held in Novosibirsk that the first open competition will be launched in the second half of 2027. The institute is responsible for commissioning the construction of this large-scale scientific facility. Bukhtiyarov noted that SKIF is scheduled to receive synchrotron radiation and conduct its first experiments in the autumn. Construction of the facility was completed in June 2026, with an opening ceremony held in August 2026. Once operational, SKIF will use synchrotron radiation to help...

2026-08-27

IAEA 70th General Conference to Host Nuclear Energy Side Events

The International Atomic Energy Agency (IAEA) Department of Nuclear Energy will hold its regular Nuclear Power Plant Operators Forum and three nuclear energy-related side events during the 70th IAEA General Conference, to be held from 14 to 18 September 2026 in Vienna, Austria. The schedule of the side events will be announced once confirmed. The Nuclear Power Plant Operators Forum, themed "Microreactors: Shaping New Operational Landscapes and Applications," is scheduled to take place from 10:30 to 12:30 on 17 September 2026 in Meeting Room CR3, 7th Floor, Building C. The forum will feature panel discussions with industry and technical experts, presenting international progress in microreactor development and deployment, covering topics such as key design features, emerging technologies, fuel and deployment options, as well as practical considerations in installation and operation, and experience from projects under construction. The session will also address the diversification of microreactor designs, the evolving research and development landscape, and the impact of practical applications, societal factors, and market expectations on technology selection.

2026-08-26

Molecular Partners Advances DLL3 Radiopharmaceutical MP0712 to Higher Dose Cohort

Swiss clinical-stage biotechnology company Molecular Partners AG recently announced its business progress and financial results for the first half of 2026. The company stated that its DLL3-targeting radioactive DARPin therapy MP0712 has advanced to the second therapeutic dose level in a U.S. multicenter Phase 1/2a clinical study, and patient enrollment for the new dose cohort is currently underway. MP0712 is a radiopharmaceutical targeting the tumor-associated antigen DLL3, carrying a therapeutic alpha-emitting radionuclide lead-212 (Pb-212) payload, co-developed by Molecular Partners and Orano Med, primarily for small cell lung cancer and other neuroendocrine tumors. According to the company's disclosure, the first dose cohort of MP0712...

2026-08-26

Ministry of Ecology and Environment North China Regional Office of Nuclear and Radiation Safety Supervision Conducts Supervision of First Fuel Loading at Tianwan Nuclear Power Plant Unit 7

Recently, the first fuel loading of Unit 7 at Tianwan Nuclear Power Plant was officially initiated, with the first fuel assembly successfully loaded into the reactor core, marking the unit's formal transition into the commissioning phase with nuclear operation. This unit is a key cooperative project witnessed by the heads of state of China and Russia via video link at its groundbreaking ceremony. This fuel loading marks a significant milestone achievement in the largest strategic cooperation project in China-Russia nuclear energy cooperation. As a core and critical procedure in nuclear power engineering, the first fuel loading serves as a comprehensive and holistic verification of the unit's engineering construction quality, system commissioning effectiveness, and safety control capabilities, and is of decisive significance to the subsequent safe and stable operation of the unit. The Ministry of Ecology and Environment North China Regional Office of Nuclear and Radiation Safety Supervision (hereinafter referred to as the North China Regional Office) has consistently upheld the nuclear safety regulatory work style of "rigorous, prudent, meticulous, and practical," closely focusing on the core and critical aspects of the first fuel loading, and implementing full-coverage, full-chain, and whole-process supervision and control over this fuel loading operation, effectively safeguarding the safety and quality defense line of the loading operation.

2026-08-26

Novartis Files Localized Production Application in China for Lutetium [177Lu] Vipivotide Tetraxetan

On August 24, information on the website of the Center for Drug Evaluation (CDE) of China's National Medical Products Administration showed that Novartis' nuclear medicine product Lutetium [177Lu] Vipivotide Tetraxetan had a localized production application submitted in China. On the same day, two indications for the drug were proposed for priority review, and the relevant review matters may correspond to this localized production application. Lutetium [177Lu] Vipivotide Tetraxetan, namely 177Lu-PSMA-617, is a radioligand therapy (RLT) drug acquired by Novartis following its acquisition of Endocyte. The drug consists of a small-molecule compound targeting prostate-specific membrane antigen (PSMA) conjugated to the therapeutic radionuclide Lutetium-177. Upon entering the bloodstream, the drug binds to prostate cancer cells expressing PSMA, and...

2026-08-25